CA-HPC-AI-ADVISORY
The HPC-AI Advisory Council (HPCAIAC) and Swiss National Supercomputing Centre (CSCS) in collaboration with the HPCXXL Board today announced the call for session proposals and sponsors for the 10 th annual Swiss Conference and HPCXXL User Group in Lugano, Switzerland, 01-04 April, 2019. Proposals for contributed talks, tutorials and workshops must be submitted before the end of January. Marking ten years, the jointly organized forum combines thought leadership talks with immersive breakout sessions across HPC and AI domain and disciplines, breakthrough research, state-of-the-art technologies, advanced initiatives, Cloud, EuroEXA, OpenStack and more.
Hosting a recognizable lineup of industry leaders like annual supporters Atos, Docker, HPCXXL partners and numerous others, the conference draws renowned subject matter experts together to share insights on leading-edge innovations, disciplines and research. Reflective of its diverse audience, annual agendas address a broad range of interests and feature trending topics from the EU’s decade long Human Brain Project involving hundreds of scientists, universities and research centers to the more than 6000 scientists, physicians and professionals supported by Novartis’ Institute of Bioinformatics Research (NIBR) to enable life-changing discoveries worldwide.
“HPC and AI are driving major advances in every field and exposing entirely new approaches from how we work to the delivery of results,” said Gilad Shainer, HPC-AI Advisory Council Chairman. “Whether developing interests, keeping pace, or to gain new knowledge, specialists from all over the world come to Lugano to delve into the newest learnings, technologies and techniques that can be applied to push boundaries even further.”
“These conferences inspire truly advantageous outcomes,” said CSCS’ HPC System Manager, Hussein Harake. “Bringing multi-disciplined private and public professionals together to contribute experiences and expertise and explore works helps further our individual pursuits. It’s also a great catalyst in surfacing opportunities for more cross-industry collaborations which benefits everyone.”
In parallel to inviting sponsor and expert submissions, registration is open through 24 Mar., 2019 , required of all participants and includes a nominal attendee fee. Open to all interested, the Swiss Conference (CHF 180.00) includes an evening excursion, daily break and lunch services. Participation in the HPCXXL meeting also requires a separate registration for all participants (CHF 90.00). Attendees must register before 10 Feb., 2019 to take advantage of Early-bird discounts. More information on the conference, key dates, submissions, etc., is on the HPCAIAC website .
About HPC-AI Advisory Council
Founded in 2008, The HPC-AI Advisory Council (HPCAIAC) is a for community benefit organization with over 400 members committed to promoting HPC and AI through education and outreach. More: www.hpcadvisorycouncil.com
About Swiss National Supercomputing Centre
Founded in 1991, the Swiss National Supercomputing Centre (CSCS) provides key capabilities to solve important problems to science and/or society. Operated by ETH Zurich, CSCS supports researchers globally from its state of the art centre in Lugano. More: www.cscs.ch
View source version on businesswire.com: https://www.businesswire.com/news/home/20181204005334/en/
Contact:
Cydney Ewald Stevens cydney@hpcadvisorycouncil.com
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
30 Peer-Reviewed Studies Highlight Statistically Significant Health Benefits of Almased16.7.2025 09:15:00 CEST | Press release
Two recent, peer-reviewed clinical studies have found that Almased, a high-protein, low-glycemic meal replacement, delivers significant health benefits ranging from weight loss and improved metabolic health to anti-aging effects and enhanced quality of life. Both reviews synthesize 30 peer-reviewed clinical studies across three decades of scientific research, confirming that Almased is effective and safe for weight reduction, preservation of lean muscle mass, and cardiovascular health. The 2025 review in the American Journal of Biomedical Science & Research highlighted Almased’s efficacy and safety for wide groups of people including individuals seeking weight loss, those with metabolic syndrome or fatty liver, older adults needing to preserve muscle mass, and athletes or healthy-weight individuals who require additional high-quality protein. This review also discusses how Almased’s patented fermentation process produces over 80 bioactive peptides, including 2 times the average daily i
The Future of Connectivity Starts Here: Network X Returns to Paris October 14 - 1616.7.2025 09:00:00 CEST | Press release
Show Reconvenes at Paris Expo Porte de Versailles with Global Representation of Industry Leaders and Telco Experts Network X 2025 - the only event that brings the fixed and mobile markets together - returns to Paris Expo Porte de Versailles October 14 - 16. Built for telecom's top players, this annual show drives business model innovation and monetisation of next-generation fixed, mobile, satellite and transport networks through AI and cloud. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250716595903/en/ Speaker on Headliners Stage at Network X 2024 New to Network X in 2025 are specialty events designed to deliver expert insights on trending topics including Data Center World and two Expo Stages for Fixed-Line and Mobile. More than 5,500 telco network infrastructure professionals will gather alongside 1,500 telcos to learn from six program tracks highlighting the latest advancements in Fibre, Wi-Fi Networks and Services, IP
Skechers AERO Series Opens New Chapter of Technical Running Innovation16.7.2025 09:00:00 CEST | Press release
New Collection Features an Evolution in Design that Cuts Through the Wind for That Aerodynamic Feel on Every Run Skechers Performance opens a new chapter of running innovation with the arrival of the Skechers AERO series. Named for the aerodynamic feel of the design, Skechers AERO represents the latest evolution of technical running shoes from the brand. The collection is engineered to deliver an exhilarating blend of speed, style and comfort to help runners cut through the wind and push beyond their personal bests while logging miles. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250716754749/en/ Introducing the Skechers AERO Series of technical running shoes: Skechers AERO Burst, Skechers AERO Spark, and Skechers AERO Tempo (L-R). “Recently launched in North America and Asia, the AERO Series leverages innovative technologies to elevate our signature comfort that’s now available to runners in Europe,” said Ben Stewart, Vic
4Moving Biotech Enrolls First Patient in Phase 2a Trial of 4P004, a Potential First-in-Class GLP-1 Therapy for Knee Osteoarthritis16.7.2025 07:00:00 CEST | Press release
- First patient enrolled in INFLAM MOTION, a global randomized Phase 2a trial including 129 knee osteoarthritis patients - 4P004 to be evaluated over 3 months for dual efficacy: symptom relief and synovial health improvement via contrast-enhanced MRI - Topline results expected in the second half of 2026 4Moving Biotech (4MB), a spin-off of 4P-Pharma dedicated to developing first-in-class treatments that modify the natural course of knee osteoarthritis (OA), today announced that the first patient has been enrolled in Phase 2a clinical trial, INFLAM MOTION. The study will evaluate 4P004, an intra-articular GLP-1 analog, as a potential first-in-class therapeutic candidate for knee osteoarthritis. INFLAM MOTION is a multicenter, randomized, double-blind, placebo-controlled Phase 2a trial planned to be conducted across Europe, the United States, and Canada. A total of 129 patients worldwide diagnosed with knee OA will be enrolled to evaluate, for the first time in humans, the efficacy of 4P
Belkin Achieves Qi2.2 Certification for Its Upcoming Products, Unlocking the Future of 25W Wireless Charging15.7.2025 19:06:00 CEST | Press release
With Qi2.2 certification, Belkin reinforces its commitment to quality, safety, and performance for the next generation of wireless charging Belkin, a leading consumer electronics brand for over 40 years, today announced it has received official Qi2.2 certification from the Wireless Power Consortium (WPC) for its upcoming products. As one of the first accessory brands to deliver Qi2.2-certified devices, Belkin is helping bring the next generation of wireless charging to market – enabling faster wireless charging speeds, broader compatibility, and improved performance for consumers. Belkin’s close partnership with the WPC since 2015 has been instrumental in bringing these advancements to consumers. As an early adopter and long-time contributor to WPC standards, Belkin was selected as one of a small group of trusted manufacturers to test and certify Qi2.2 products ahead of the broader industry rollout. All Belkin products undergo rigorous safety, quality, and performance testing. The comp
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom